

mized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. *J Clin Oncol.* 2009;27:1268-74.

37. Van Den Bent M, Eoli M, Sepulveda JM, et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro Oncol.* 2020;22:684-93.

38. Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol.* 2022;23:53-64.

39. Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed,

EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol.* 2017;18:1373-85.

40. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol.* 2021;18:170-86.

41. Wick A, Bähr O, Schuler M, et al. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. *Clin Cancer Res.* 2021;27:2723-33.

42. Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro Oncol.*

2019;21:95-105.

43. Wick A, Kessler T, Platten M, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT growth in combination with temozolomide. *Neuro Oncol.* 2019;21:189-200.

44. Yamashita AS, da Costa Rosa M, Borodovsky A, et al. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma promoter methylated malignant astrocytoma. *Neuro Oncol.* 2020;22:1162-72.

45. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. *J Pathol.* 2012;226:7-16.

ON-LINE KURZ

On-line kurz pro praktické neurology 2022

Trendy v léčbě migrény

PŘEDNÁŠKY

- Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN
- Medication overuse headache a role anti-CGRP – MUDr. Petra Migalová
- Lékové interakce migrény a RS – update – PharmDr. Josef Suchopár
- Výhody flexibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská

ODBORNÝ GARANT

MUDr. Jolana Marková, FEAN
Neurologická klinika, Fakultní Thomayerova nemocnice v Praze

POČET KREDITŮ **2**

Registrace ZDARMA

TERMÍN

prosinec 2022
až listopad 2023
dostupný na
online.solen.cz

PARTNER

teva

